In particular, combining CD40 inhibition with anti-TNF or anti-IL-23 agents may achieve synergistic effects by simultaneously targeting innate and adaptive immune pathways, thereby offering novel therapeutic avenues for CD patients. The gene discussed is CD40; the disease is Cowden disease.